Expression of Survivin, Estrogen Receptor and Progesterone Receptor of Endometrium of Patients With Anovulatory Dysfunctional Uterine Bleeding Before and After Radiofrequency Heat-Coagulation Treantment

To investigate the mechanism of radiofrequency(RF) heat-coagulation treatment of anovulatory dysfunctional uterine bleeding (DUB) by testing the expression levels of survivin, estrogen receptor(ER) and progesterone receptor (PR) in endometrium before and half year after treatment.

From June 2003 to December 2008, 76 cases of endometrium with anovulatory dysfunctional uterine bleeding had undergone radiofrequency heat-coagulation treatment in the Department of Gynecology, the Military General Hospital of Jinan PLA. Pathological diagnosis of endometrial tissue from diagnostic curettage showed that 32 cases of simple hyperplasia, 28 of complex hyperplasia, and 16 of proliferative endometrium before treatment. A total of 76 cases were divided into A-type RF group and B-type RF group according to different ways of radiofrequency. A-type RF group conducted all endometrial coagulation-A-type coagulation, and B-type RF group conduced all endometrial coagulation-B-type coagulation. At the same time, another thirty-eight cases with anovulatory dysfunctional uterine bleeding women were treated by conservative treatment (control group). Pathological diagnosis of endometrial tissue from diagnostic curettage showed that 16 cases of simple hyperplasia, 12 of complex hyperplasia, and 10 of proliferative endometrium before treatment. Other gynecological diseases and gynecological cancer were not found in both two groups. All of them had not received any hormonal treatment measures nearly a month. Informed consent was obtained from all participants. There was no significant difference of age between two groups (P>0.05). The expression levels of survivin, estrogen receptor and progesterone receptor were detected by immunohistochemical S-P method before and follow-up 6 to 12 months after the treatment.

①Pathological types of endometrial tissue from diagnostic curettage before and follow-up 6 to 12 months after treatment showed no significant difference of control group (P>0.05). ② Expressive levels of survivin, estrogen receptor and progesterone receptor after the treatment had no significant difference between two groups (P>0.05). Pathological types of endometrial tissue from diagnostic curettage of study group showed significant difference before and follow-up 6 to 12 months after the treatment of study group (P<0.01). Pathological types of endometrial tissue from diagnostic curettage showed significant difference in follow-up 6 to 12 months after treatment between two groups (P<0.01). In 6 to 12 months after treatment, endometrium were placed by granulation tissue in A-type RF group, and pathological types of endometrial tissue by diagnostic curettage showed some endometrial glands and granulation tissue. ③ Before the treatment of control group, survivin, estrogen receptor and progesterone receptor expressed in simple hyperplasia, complex hyperplasia, and proliferative endometrium. Positive value among them had no significant difference (P>0.05). ④There were obviously statistical decrease of expressive levels of survivin, estrogen receptor and progesterone receptor after radiofrequency treatment in half a year than those before the treatment of study group (P<0.05).

The continued lower levels of survivin, estrogen receptor and progesterone receptor of the anovulatory dysfunctional uterine bleeding patients in study group is one of the important mechanism for treating anovulatory dysfunctional uterine bleeding by radiofrequency method. | 1 Yue J, ed．Obstetrics and gynecology．7th ed [M]．Beijing: People's Medical Publishing House, 2008, 301-308．[乐杰，主编．妇产科学．7版[M]．北京：人民卫生出版社，2008, 301-308.] | | | 2 Sun AJ．The treatment of disfunctional uterine bleeding using sex hormone [J]．Chin J Pract Gynecol Obstet, 2006, 22(9) : 650-651．[孙爱军．功能失调性子宫出血的性激素治疗[J]．中国实用妇科与产科杂志，2006, 22(9): 650-651.] | | | 3 Taskin O, Onoglu A, Inal M, et al. Long-term histopathologic and morphologic changes after thermal endometrial ablation[J]. J Amassoc Gynecol Laparosc, 2002, 9(2): 186-190. | | | 4 Li D．The curative effect of RU486 for the treatment of disfunctional uterine bleeding[J]．Chin J Mod Drug Appl, 2009, 3(20): 104-105．[李丹．应用米非司酮治疗功血的临床观察[J]．中国现代药物应用，2009, 3(20): 104-105.] | | | 5 Yin GP, Chen M, Shao X, et al．Radiofrequency minimally invasive treatment of uterine benign diseases[J]．Prog Obstet Gynecol, 2003, 12(3): 200-203．[尹格平，陈铭，邵旭，等．射频热凝固微创治疗子宫良性病变的初步研究[J]．现代妇产科进展，2003, 12(3): 200-203.] | | | 6 Yin GP, Chen M, Zhu TY, et al. Radiofrequency heat-coagulation minimal invasive treatment of adenomyoma and adenomyosis of uterine[J]. Chin J Clin Obstet Gynecol, 2003, 4(6): 410-412. [尹格平，陈铭，朱彤宇，等．射频热凝固微创治疗子宫肌腺瘤和腺肌病[J]．中国妇产科临床杂志，2003, 4(6): 410-412.] | | | 7 Masatsugu U, Yoshiki Y, Mikio T, et al. Survivin gene expression in endometriosis[J]. J Clin Endocrinol Metab, 2002, 87(7): 3452-3459. | | | 8 Takai N, Miyazaki T, Nishida M, et al. Survivin expression correlateswith clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma[J]. Cancer Lett, 2002, 184(1): 105-116. | | | 9 Borbely AA, Murvai M, Konya J, et al. Effects of human papillomavirus type 16 oncoproteins on survivin gene expression[J]. J Gene Virol, 2006, 89(pt22): 287-294. | | | 10 Hyder SM, Huang JC, Nawaz Z, et al. Regulation of vascular endothelial growth factor expression by estrogens and progesterons[J]. Environ Health Perspect, 2000, 108(Suppl 5): 785-790. | | | 11 Yin GP．Progress in radiofrequency heat-coagulation minimal invasive treatment of uterine benign diseases[J]．Chin J Pract Gynecol Obstet, 2007, 23(8): 641-643．[尹格平．射频热凝固治疗子宫良性疾病的进展[J]．中国实用妇科与产科杂志，2007, 23(8): 641-643.] | | [1] | 巨淑慧, 庞嘉越成, 皮浩, 蒋英杰, 李恒宇, 盛湲. ESR1基因突变在雌激素受体阳性转移性乳腺癌中的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2023, 17(01): 40-43. | | [2] | 张蓝心, 高天琦, 徐岭植, 李曼. 激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的治疗进展[J/OL]. 中华乳腺病杂志(电子版), 2022, 16(06): 365-369. | | [3] | 陈圣, 朱明华, 黄焰, 王怀涛, 何奇. 乳腺癌新辅助化疗后雌、孕激素受体表达变化的临床意义[J/OL]. 中华乳腺病杂志(电子版), 2021, 15(06): 346-351. | | [4] | 李晶晶, 王小磊, 任鹏飞, 杨震, 陈婵娟, 琚倩, 李烦繁. 氟维司群单药对激素受体阳性复发、转移性乳腺癌患者疗效的单中心分析[J/OL]. 中华乳腺病杂志(电子版), 2020, 14(03): 150-155. | | [5] | 张光君, 王唯依, 黄雨, 涂刚. G蛋白偶联雌激素受体mRNA表达与乳腺癌患者临床病理特征及预后的关系[J/OL]. 中华乳腺病杂志(电子版), 2020, 14(01): 32-36. | | [6] | 高德宗. 激素受体阳性晚期转移性乳腺癌的内分泌治疗[J/OL]. 中华乳腺病杂志(电子版), 2018, 12(02): 69-72. | | [7] | 岳丰莉, 潘沁汶, 邓长容. 延长辅助内分泌治疗对比5年标准治疗对雌激素受体阳性早期乳腺癌患者预后影响的Meta分析[J/OL]. 中华乳腺病杂志(电子版), 2018, 12(01): 37-42. | | [8] | 曹杨, 刘颖蕾, 刘宏斌, 周峰, 乔海风, 开海丽, 刘曼华. 蜕膜组织种植建立子宫内膜异位症模型的可行性分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2018, 14(02): 193-198. | | [9] | 杨伟, 陈洁静. 雌激素受体β与结直肠癌临床病理特征及预后关系的Meta分析[J/OL]. 中华普通外科学文献(电子版), 2020, 14(06): 475-480. | | [10] | 曾益为, 刘仁斌. 雌激素受体β水平预测乳腺癌预后的研究进展[J/OL]. 中华普通外科学文献(电子版), 2019, 13(01): 58-62. | | [11] | 姜华, 李梓雄, 程林, 王佳妮, 黄勇, 李玺, 刘仁斌. 雌激素受体β1在MDA-MB-231人乳腺癌细胞中高表达对雷诺昔芬抗肿瘤作用的影响[J/OL]. 中华普通外科学文献(电子版), 2018, 12(01): 14-18. | | [12] | 陈珊, 胡智强, 张月明, 唐定, 黎蒙, 赵帅. Orai1、Orai3在乳腺癌组织中的表达及与病理学指标的相关性分析[J/OL]. 中华普外科手术学杂志(电子版), 2023, 17(05): 514-517. | | [13] | 金佳佳, 李姿萱, 李永超, 宋渐石, 王冰霜, 辛鸣, 徐梦圆, 王文娟, 刘冉, 王雪, 聂亚雄, 张晓琳. 雌激素受体α基因rs2234693多态性与绝经后妇女骨质疏松症的meta分析[J/OL]. 中华老年骨科与康复电子杂志, 2021, 07(06): 372-378. | | [14] | 陈钟玉, 井水. 高通量测序技术在稽留流产孕妇绒毛染色体异常观察中的价值及其发病的影响因素分析[J/OL]. 中华临床医师杂志(电子版), 2021, 15(12): 1003-1008. | | [15] | 杨艳, 张文, 金晶, 封淏, 孙红光, 丁永玲, 诸林海. 乳腺浸润性导管癌超声特征与ER、PR、CerB-2、Ki-67表达的相关性[J/OL]. 中华临床医师杂志(电子版), 2019, 13(05): 333-338. | | 阅读次数 | ||||| | 全文 | | |||| | 摘要 | | |||| 版权所有 中华医学会 中华医学电子音像出版社有限责任公司 京ICP备14006079号-1 网络出版服务许可证：(署)网出证(京)字第075号 AI 小 编 AI小编